Best Life Sciences Companies in Kansas, United States
The 57 best Life Sciences companies in Kansas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cingulate.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Kansas
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cingulate Developer of therapeutics for the treatment of ADHD | $33M | 11 mo ago | Public | 15 | Shane Schaffer Co-Founder & CEO | WordPressDrupalApple iCloud Mail+31 | — | 1 launch |
| 2 | Spinal Simplicity Developer of minimally invasive devices for spinal problems | $15M | 19 mo ago | Series B | 44 | — | WordPressApple iCloud MailMySQL+25 | 245 patents Patents concentrated in health & consumer products | — |
| 3 | Micron Pure Provider of decontamination solutions to clean airborne pathogens | $14M | 28 mo ago | Series B | — | John Bergida Founder & CEO | — | — | — |
| 4 | Shift Pharmaceuticals Developer of targeted therapeutics for neuromuscular disorders | $13M | 49 mo ago | Funding Raised | 7 | Steve Connor CEO | — | — | — |
| 5 | Pinnacle Technology Neurological tools for preclinical CNS data acquisition and analysis | $12M | 37 mo ago | Funding Raised | 30 | — | — | 51 patents Real-time music-synced LED lighting control and modular lighting hardware systems. | — |
| 6 | Flow Forward Medical Provider of a wearable medical device to facilitate vascular access in hemodialysis patients | $11M | 73 mo ago | Acquired | 61 | — | — | — | — |
| 7 | Metactive Medical Online casino offering Mahjong Ways slot game with high RTP | $10M | 100 mo ago | Series A | 31 | — | — | — | — |
| 8 | TVAX Biomedical Targeted T cell-based immunotherapies for brain cancer & renal cell carcinoma. | $10M | 45 mo ago | Series A | 6 | Lowell Tilzer CEO | — | — | — |
| 9 | NeoTherma Oncology Provider of thermal treatment for the removal of deep solid tumors | $6M | 35 mo ago | Series A | 6 | — | — | 29 patents Targeted deep tissue hyperthermia via time-shared RF inductive applicators for oncology | — |
| 10 | Amplifi Vascular Developer of a blood pump technology intended to enlarge veins | $6M | 22 mo ago | Seed | — | Sean Morris CEO | — | — | — |
| 11 | Innara Health Provider of premature neonatal feeding solutions | $6M | 51 mo ago | Series A | 14 | — | — | — | — |
| 12 | Evogen Neurology proteomics, genomics, precision medicine, reagent technology, and threat detection | $5M | 76 mo ago | Series B | 13 | — | — | 26 patents Molecular biomarkers for diagnosing and differentiating epileptic versus non-epileptic seizures | — |
| 13 | Phoreus Biotech Provider of a nano-delivery platform for genetic vaccines and therapeutics 14Talent top 38%Tech top 50%Funding bottom 48%Global bottom 30% All 5 signals ▾Talenttop 38% Techtop 50% Fundingbottom 48% Globalbottom 30% Marketbottom 18% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Tech: 29 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 14/100 | $4M | 8 mo ago | Seed | 6 | Randall Tosh Founder & CEO | WordPressMySQLPHP+26 | — | — |
| 14 | Acenxion Biosystems Developer of phenotypic AST devices forcandidate antibiotic or precision patient treatment | $4M | 23 mo ago | Series A | 10 | Roy Swiger Chief Executive Officer | — | — | — |
| 15 | Likarda Developer of 3D cell cultures for regenerative medicine | $4M | 58 mo ago | Series A | 11 | Lisa Stehno-Bittel President and Co-Founder | WordPressApple iCloud MailGoogle Workspace+20 | 40 patents Hydrogel microparticle systems for biomedical fillers, drug delivery, lubricants, and cold‑chain preservation | — |
| 16 | OsteoGeneX Small molecule against the validated target Sclerostin to increase bone density | $3M | 158 mo ago | Funding Raised | — | Debra Ellies Founder & CEO | — | 50 patents Small‑molecule therapeutics for enhancing bone growth and regeneration | — |
| 17 | OssiFi Innovative bone-biology company developing therapeutics and medical devices for bone health | $2M | 92 mo ago | Seed | 2 | Debra Ellies Founder & CEO | — | 10 patents Osteogenic therapeutics targeting SOST/Wnt pathway and harmine derivatives for bone growth | — |
| 18 | Mobility Designed Provider of devices for disabled people to support themselves with elbows and forearms | $2M | 90 mo ago | Seed | 8 | Liliana Younger Co-Founder | — | 48 patents Design and ergonomic improvements for medical crutches and mobility support devices. | — |
| 19 | Nectagen Provider and developer of nanoCLAMP Single Domain Antibody Mimetics for research application | $1M | 24 mo ago | Funding Raised | — | Richard Suderman Director | — | 11 patents Engineered thermostable protein scaffolds and affinity reagents for biotechnological applications | — |
| 20 | Orion Integrated Bioscience Solving global health, trade, and security challenges through biotechnology and AI | $1M | 211 mo ago | Funding Raised | — | Willy A. Valdivia Founder & CEO | — | — | — |
| 21 | Novadiol Developer of therapies for treating kidney diseases | $1M | 144 mo ago | Funding Raised | 3 | G Georges CEO | — | — | — |
| 22 | Love Lifesciences Developer of hybrid injection devices for medication delivery | $724K | 36 mo ago | Seed | 2 | Nick Love Co-Founder & CEO | — | — | 1 partnership |
| 23 | VasoGenix Pharmaceuticals Biotechnology company specializing in reagents, kits, and assays for life science research | $600K | 209 mo ago | Early Stage | — | Gary Rosenthal Co-Founder | — | — | — |
| 24 | Prommune Macau lottery data provider offering results, analysis, and prize information | $528K | 129 mo ago | Funding Raised | — | Anna Sanderson Co-Founder | — | 7 patents Immunological vaccines and therapeutics targeting parasitic infections | — |
| 25 | TiFiber Nanofiber Membrane Technology for controlling dangerous microorganisms | $472K | 138 mo ago | Deadpooled | — | Calvin Goforth CEO | — | — | — |
| 26 | Madeira Therapeutics Commercialization of currently approved adult drugs reformulated specifically for children. | $420K | 183 mo ago | Deadpooled | — | Peter Joiner CEO | — | — | — |
| 27 | ImpeDx Rapid diagnostics for blood infections | $335K | 84 mo ago | Deadpooled | — | Steve O'Connor CEO | — | — | — |
| 28 | Vitalograph Respiratory diagnostics and clinical trial solutions for improved patient health | $112K | 130 mo ago | Funding Raised | 238 | Frank Keane CEO | Apple iCloud MailAmazon Web ServicesVue.js+16 | — | — |
Top 12 Life Sciences companies in Kansas
#1
Public · Kansas City, Kansas · founded 2012 · 15 employees$33Mraised▾
Developer of therapeutics for the treatment of ADHD. The product CTx-1301 has dexmethylphenidate and CTx-1302 has dextroamphetamine formulation which utilizes the company's precision timed-release drug delivery platform. The platform has an erodible barrier layer that helps in controlled drug release.
- Jul 2025Post IPO$25M
- Apr 2025Grant (prize money)$3M
- Jan 2024Post IPO$219.8K
- Jan 2018Series B$6.8M
#2
Seed · Olathe, Kansas · founded 2018 · 6 employees$4.5Mraised▾
Provider of a nano-delivery platform for genetic vaccines and therapeutics. It provides users with a company that offers Branched Amphipathic Peptide Capsules and Corralling Amphipathic Peptide Colloids which are nanocarrier that helps in delivering vaccines, cancer therapies, alternative antibiotics, and biopesticides. Their solvent-filled bilayer delineated capsules enable the encapsulation of fluorescent dyes, therapeutic drugs, and radionuclides.
- Nov 2025Seed$420.7K
- Dec 2022Seed$2M
- Jul 2020Seed$4.4M
- Jul 2019Seed$550K
#3
Series B · Lenexa, Kansas · founded 2008 · 44 employees$15Mraised▾
Developer of minimally invasive devices for spinal problems. It offers MinutemanG3, an interspinous inter-laminar fusion device that provides relief from spinal ailments, such as spondylolisthesis, central and foraminal lumbar stenosis, and degenerative disc diseases. Its other product, the patent-pending G2-inserter, allows for quick and accurate placement of the MinutemanG3 device. The device has both FDA clearance and the European CE Mark.
- Dec 2024Series B$6.1M
- Mar 2022Series B$10.9M
- May 2016Series A—
- Oct 2014Series A$250K
#4
Seed · Prairie Village, Kansas · founded 2023$5.9Mraised▾
Developer of a blood pump technology intended to enlarge veins. It provides the Amplifi Vein Dilation System, a novel device designed to enlarge veins using a proprietary blood pump technology. It specializes a wearable external blood pump designed to enhance the success of AVF procedures by enhancing vein diameter and blood flow.
- Aug 2024Seed$5.9M
#5
Series A · Kansas City, Kansas · founded 2020 · 10 employees$4.1Mraised▾
Developer of an automated antimicrobial susceptibility testing system intended to detect gonorrhea bacteria in blood cultures. The company's AST system seamlessly fits into the current clinical workflow and reduces the time required for phenotypic AST results, enabling clinicians to provide precise, targeted treatment and minimizing antibiotic exposure to AMR pressures.
- Jul 2024Series A$1.1M
- Apr 2023Seed$50K
- Jan 2021Grant (prize money)$2.9M
#6
Series B · Olathe, Kansas · founded 2020$14.2Mraised▾
Provider of decontamination solutions to clean airborne pathogens. The company has "CerroZone" which uses ozone technology to eliminate all pathogens including COVID-19, influenza, common cold viruses, and bacteria. It has applications for schools, hospitals, businesses, churches, and more.
- Mar 2024Series B$150K
- Oct 2022Series B$14M
#7
Funding Raised · Lawrence, Kansas · founded 1995 · 30 employees$12.1Mraised▾
Neurological tools for preclinical CNS data acquisition and analysis. The company specializes in researching, designing, and manufacturing turn-key solutions for preclinical Central Nervous System data acquisition and analysis. They offer sophisticated new tools that improve and simplify research. The company provides products and software for data analysis. They are a technology company in the B2B space. They offer multiple products and services.
- 2023Grant (prize money)$288.5K
- 2019Grant (prize money)$2.7M
- 2013Grant (prize money)$1.2M
- 2012Grant (prize money)$2.5M
#8
Funding Raised · Kansas City, Kansas · founded 2007$1.2Mraised▾
Nectagen engages in developing and selling nanoCLAMP antibody mimetics for research applications. These are used for purification of native protein complexes. nano Clostridial Antibody Mimetics are based on a 16 kD beta-sandwich scaffold derived from the NagH hyaluronidase of Clostridium perfringens. The company has engineered the monomeric scaffold to contain three variable loops similar to the complementarity-determining region of immunoglobulins. nanoCLAMPs are ten times smaller than antibodies and more easily engineered, with the standard variant containing a unique cysteine for conjugation.
- Jul 2024Grant (prize money)$275K
- May 2023Grant (prize money)$261.1K
- Aug 2021Grant (prize money)$252.5K
- Jul 2019Grant (prize money)$150K
#9
Series A · Wichita, Kansas · founded 2015 · 6 employees$6Mraised▾
NeoTherma Oncology is a medical device company developing a radio frequency (RF) thermal treatment for deep, solid tumors that is expected to increase the effectiveness of current cancer treatments, aiming to minimize the harshest effects of chemotherapy and radiation. The company's device is the Vectron thermal oncology system, consisting of a non-invasive technology integrates with the existing MRI treatment suites. Vectron emits an image-guided non-ionizing electromagnetic field to produce local ‘fever-range’ temperatures in tumor tissue, intended to increase the effectiveness of anticancer radiotherapy, chemotherapy, and immunotherapy.
- Aug 2023Grant (prize money)$65.8K
- Aug 2018Series A$6M
#10
Series A · Lenexa, Kansas · founded 2004 · 6 employees$9.5Mraised▾
TVAX Biomedical focuses on the development of targeted cell-based immunotherapies for the treatment of cancer. Its proprietary immunologic treatment, TVAX Immunotherapy, uses a patient’s cells to create cancer-killing T-cells that could destroy the patient’s cancer cells, including cancer stem cells. The company’s lead treatment candidate is TVI-Brain-1 for the treatment of astrocytoma and of glioma. Its TVAX Immunotherapy candidate is TVI-Kidney-1, which is for the treatment of stage 4 renal cell carcinoma.
- Sep 2022Grant (prize money)$386.4K
- Jul 2016Conventional Debt$325.1K
- Mar 2015Series A$2M
- Dec 2012Series A$2M
#11
Funding Raised · Overland Park, Kansas · founded 2018 · 7 employees$12.6Mraised▾
Developer of targeted therapeutics for neuromuscular disorders. The company is developing innovative treatments focused on neuromuscular and genetic disorders using advanced oligonucleotide-based technologies. It is advancing a genetic drug designed to increase the expression of the SMN2 protein, which is deficient in SMA patients.
- Jun 2022Grant (prize money)$256.6K
- Sep 2019Grant (prize money)$228.1K
- Sep 2018Grant (prize money)$12.1M
#12
Series A · Olathe, Kansas · founded 2007 · 14 employees$5.8Mraised▾
Provider of premature neonatal feeding solutions. The company's flagship product, NTrainer System is FDA cleared and revolutionized care models for preterm and newborn infants. The NTrainer System fosters skills essential to non-nutritive suck (NNS) development - a vital skill that has been linked to faster transitions to oral feeds, more rapid weight gain, shortened hospital stays, and reduced hospital costs. The product is an evidence-based technology, which is used in neonatal and pediatric, cardiac intensive care units. The NTrainer System helps in the assessment and treatment of dysfunctional oral motor skills. Investors include Open Prairie Ventures, Kansas Bioscience Authority, Flyover Capital, Quest Capital Alliance, EdVentures.
- Apr 2022Series A—
- Jul 2018Conventional Debt$1.5M
- Oct 2016Series A—
- Apr 2016Conventional Debt$1.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Kansas is moving
A read on the academic research around Biotechnology in Kansas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 108 papers.
Kansas State University leads optimistic agricultural biotechnology research, focusing dominantly on crop and livestock genetics—particularly wheat, barley, and animal traits—with cautiously advancing momentum.
- Kansas State University31
- University of Arkansas at Fayetteville22
- University of Arkansas System15
- University of Arkansas for Medical Sciences14
- University of Kansas Medical Center12
- Gene5
- Population2
- Virus2
- Cell2
- Antigen2
- Germplasm5
- Biofilm3
- Antimicrobial3
- Identification (biology)3
- In vivo3
- Messenger RNA3
- Contamination2
- Antibiotic resistance2
- Food processing2
- Gene2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.